StockData

Neogen vs QuidelOrtho

NEOG and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NEOG and QDEL compare

Neogen is the larger company, worth 3.5 times as much as QuidelOrtho ($2.4B against $677M).

Neogen grew revenue faster over the last twelve months (−0.33% versus −4.5% for QuidelOrtho).

Neogen keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −14.2% at QuidelOrtho.

Neogen scores higher on the StockData Score (7 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNEOGQDEL
Size and price
Market cap$2.4B$677M
Share price$10.90$9.87
Change, 1 year70.6%−53.7%
Change, 5 years−73.5%−93.2%
Beta (5Y)0.861.32
Employees2,6366,500
StockData Score
Total score7 (better)6
Valuation score13 (better)
Growth score2 (better)0
Performance score3 (better)2
Health score11
Dividend score00
Valuation
P/S2.7×0.3× (better)
P/B1.1×0.4× (better)
EV/EBITDA34.5×10.3× (better)
P/FCF47.8×–
FCF yield2.1% (better)−17.3%
Fair value$7.32$26.64
Margin of safety−48.8%63.0% (better)
Growth
Revenue growth (TTM)−0.33% (better)−4.5%
Revenue growth, 5Y average13.2% (better)10.4%
Profitability
Gross margin47.4% (better)44.2%
Operating margin−0.83% (better)−4.9%
Net margin−6.3% (better)−14.2%
FCF margin5.6% (better)−4.5%
Return on equity−2.7% (better)−19.3%
Return on invested capital−0.17% (better)−2.2%
Financial health
Debt / equity0.74 (better)1.64
Net debt / EBITDA12.698.29 (better)
Interest coverage–−0.6×
Current ratio3.90 (better)1.36
Altman Z-score1.36 (better)0.26
Piotroski F-score66
Dividends and buybacks
Buyback yield–−0.66%
Shareholder yield0.00% (better)−0.66%
Ownership
Held by institutions109%121%
Held by insiders0.60%43.4%
Insider net buying, 12 months−$102K$669K (better)
Short interest, % of float5.9%37.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.